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Background: Preoperative anemia is independently associated with adverse 
outcomes after general and cardiac surgery. Outcomes after breast recon-
struction are not established. We assessed the effect of preoperative anemia 
on 30-day postoperative morbidity and length of hospital stay (LOS) in 
patients undergoing immediate breast reconstruction.
Methods: We identified patients undergoing immediate breast reconstruc-
tion from 2008 to 2010 from the American College of Surgeons’ National 
Surgical Quality Improvement Program database (a prospective outcomes-
based registry from hospitals worldwide). De-identified data were obtained 
for demographics, preoperative risk factors, 30-day morbidity, and LOS. 
Morbidity variables included flap/graft/prosthesis, cardiac, respiratory, 
neurological, urinary, wound, and venous thromboembolism outcomes. 
Logistic regression assessed the crude and adjusted effect of anemia (he-
matocrit <36%) on postoperative 30-day morbidity. Measures of central 
tendency of LOS were compared across increasing severities of anemia in 
patients developing adverse events versus controls.
Results: The study population included 10,958 patients; 1556 (16.74%) had 
preoperative anemia. Crude odds ratio for 30-day morbidity was significantly 
higher in anemic patients, unadjusted odds ratio = 1.33 (P < 0.008). This pre-
vailed after extensive adjustment for confounding, yielding an adjusted odds 
ratio = 1.38 (P < 0.03). Patients who experienced adverse effects had pro-
tracted LOS, and the presence of anemia significantly amplified this effect.
Conclusions: These data provide new insight into the effect of anemia in 
immediate breast reconstruction, demonstrating an independent associa-
tion between preoperative anemia and 30-day morbidity. These findings 
suggest treating anemia when possible; however, prospective studies should 
explore the efficacy, safety, and cost-effectiveness of such treatments. (Plast 
Reconst Surg Glob Open 2013;1:e30; doi:10.1097/GOX.0b013e3182a18c6f; 
 Published online 6 August 2013.)
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Hematocrit concentrations are almost always measured before elective surgeries such as breast reconstruction,1 yet few studies have 
explored the implications of preoperative low 
hematocrit on postoperative outcomes. The impact 
of preoperative anemia on postoperative outcomes 
has been analyzed in other surgeries, both cardiac 
and major noncardiac. Kulier et al,2 using the Mul-
ticenter Study of Perioperative Ischemia Epidemi-
ology II database to study data from 5065 patients 
undergoing elective coronary artery bypass graft, 
found that preoperative anemia is an independent 
predictor of postoperative morbidity, and the level 
of morbidity amplifies with the extent of baseline 
risk factors. Moreover, Wu et al,3 analyzing a cohort 
of 310,311 elderly veterans using the VA National 
Surgical Quality Improvement Program database, 
found that even mild degrees of preoperative ane-
mia are associated with increased 30-day mortality 
and adverse cardiac events. Furthermore, Musallam 
et al,4 analyzing data of 227,425 patients of all ages 
undergoing major noncardiac surgery using the 
American College of Surgeons’ National Surgical 
Quality Improvement Program (ACS-NSQIP) data-
base, found that postoperative mortality and 30-day 
morbidity was higher in patients with preoperative 
anemia.
The major subspecialties analyzed in these 
studies were general, vascular, and orthopedic. 
Although a subgroup named “plastic surgery” was 
included, none of these focused specifically on 
breast reconstruction. Available data on the effect 
of preoperative anemia on breast reconstruction 
outcomes are limited.5–8 Such articles had either bi-
ased study designs, small number of patients, failed 
to adjust for major confounders, or were restricted 
to specific subtypes of breast reconstruction. None 
described in detail the exact relationship between 
anemia and adverse outcomes or quantified the 
impact of preexisting comorbidities on this associa-
tion. It is unknown whether the effects of anemia 
on outcomes in breast reconstruction are caused by 
a low hematocrit level per se or by an association 
with other risk factors frequently prevalent in ane-
mic patients.
Therefore, the main goal of the present study 
is to examine the impact of preoperative anemia 
on postoperative adverse outcomes in patients un-
dergoing immediate breast reconstruction using 
a large prospective multicenter database (ACS-
NSQIP, Appendix, Supplemental Digital Content 1, 
http://links.lww.com/PRSGO/A3). Specifically, our pri-
mary aim is to determine whether subnormal preop-
erative hematocrit before immediate reconstruction 
is an independent predictor of 30-day morbidity. We 
evaluate a potential dose-response relationship be-
tween decreasing hematocrit levels and increasing 
postoperative morbidity. Furthermore, we examine 
the impact of comorbidities and other risk factors 
on the relationship between preoperative anemia 
and postoperative morbidity. Finally, we analyze the 
effect modification of different severity levels of pre-
operative anemia on length of hospital stay (LOS) 
in patients who developed postoperative morbidity 
(complicated cases) as compared to those who did 
not (uncomplicated cases).
PATIENTS AND METHODS
We analyzed data from the 2008 to 2010 ACS-
NSQIP databases. This database is a prospective, 
validated, risk-adjusted, outcomes-based program to 
measure and improve the quality of surgical care.9 
It provides feedback to member hospitals about 30-
day risk-adjusted surgical mortality and morbidity10,11 
and includes de-identified data for patients’ demo-
graphics, functional statuses, admission sources, pre-
operative risk factors, laboratory data, perioperative 
variables, and 30-day postoperative outcomes. For 
the purpose of our study, data were retrieved for all 
surgeries undertaken at participating medical cen-
ters (211 centers in 2008, 237 in 2009, and 258 in 
Supplemental digital content is available for this 
article. Clickable URL citations appear in the text.
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Table 1. Baseline Characteristics of Patients
No Anemia Anemia Total
P
nno anemia = 7737 nanemia = 1556 nT = 9293
83.26% 16.74% 100%
General variables
  Age, mean (SD) 52.0 (10.4) 49.4 (11.0) 51.5 (10.5) <0.0001
  Smoking, n (%) 1036 (13.4%) 169 (10.9%) 1205 (13.0%) 0.0061
  Race, n (%) <0.0001
   White 6029 (77.9%) 982 (63.1%) 7011 (75.4%)
   African American 437 (5.6%) 257 (16.5%) 694 (7.5%)
   Hispanic 388 (5.0%) 87 (5.6%) 475 (5.1%)
   Other 242 (3.1%) 78 (5.0%) 320 (3.4%)
   Missing 641 (8.3%) 152 (9.8%) 793 (8.5%)
  WRVU*, mean (SD) 15.9 (3.0) 16.1 (2.7) 15.9 (2.9) <0.0001
  General anesthesia 7706 (99.6%) 1552 (99.7%) 9258 (99.6%) 0.5014
  ASA class†, n (%) <0.0001
   I–II 6202 (80.2%) 1145 (73.6%) 7347 (79.1%)
   III 1511 (19.5%) 399 (25.6%) 1910 (20.6%)
   IV–V 19 (0.2%) 9 (0.6%) 28 (0.3%)
   Missing 5 (0.1%) 3 (0.2%) 8 (0.1%)
  Infected surgical wound class, n (%) 5 (0.1%) 7 (0.4%) 12 (0.1%) 0.0013
  Mean total operation time in min (SD) 239.6 (136.7) 236.0 (129.7) 239.0 (135.5) 0.9471
  Inpatient status, n (%) 6243 (80.7%) 1282 (82.4%) 7525 (81.0%) 0.128
  Days from admission to operation, n (%) 0.0019
   0 7700 (99.5%) 1538 (98.8%) 9238 (99.4%)
   1 27 (0.3%) 9 (0.6%) 36 (0.4%)
   >1 10 (0.1%) 9 (0.6%) 19 (0.2%)
   Missing 1 (0.0%) 0 (0.0%) 1 (0.0%)
  Perioperative transfusion‡ 132 (1.7%) 45 (2.9%) 142 (1.5%) 0.0001
  Functional status 0.0067
   Independent 7717 (99.7%) 1544 (99.2%) 9261 (99.7%)
   Partially dependent 17 (0.2%) 11 (0.7%) 28 (0.3%)
   Dependent 3 (0.0%) 1 (0.1%) 4 (0.0%)
Cardiovascular variables, n (%)
  Dyspnea at rest or with moderate exertion 299 (3.9%) 75 (4.8%) 374 (4.0%) 0.0894
  Congestive heart failure in previous 30 d 1 (0.0%) 3 (0.2%) 4 (0.0%) 0.0164
  Angina in previous 30 d 6 (0.1%) 2 (0.1%) 8 (0.1%) 0.6285
  Myocardial infarction in previous 6 mo 0 (0.0%) 2 (0.1%) 2 (0.0%) 0.028
  Previous percutaneous coronary intervention 48 (0.6%) 16 (1.0%) 64 (0.7%) 0.0909
  Previous cardiac surgery 28 (0.4%) 14 (0.9%) 42 (0.5%) 0.0107
  Hypertension requiring medication 1907 (24.6%) 399 (25.6%) 2306 (24.8%) 0.4033
  History of peripheral vascular disease 11 (0.1%) 1 (0.1%) 12 (0.1%) 0.7037
  Rest pain or gangrene 0 (0.0%) 0 (0.0%) 0 (0.0%) >0.9999
  Composite cardiovascular morbidity  
 (not including HTN)
356 (4.6%) 92 (5.9%) 448 (4.8%) 0.0321
Respiratory variables, n (%)
  Current pneumonia 0 (0.0%) 0 (0.0%) 0 (0.0%) >0.9999
  History of severe COPD 69 (0.9%) 19 (1.2%) 88 (0.9%) 0.2494
  Ventilator dependent in previous 48 h 0 (0.0%) 1 (0.1%) 1 (0.0%) 0.1674
  Composite respiratory morbidity 69 (0.9%) 20 (1.3%) 89 (1.0%) 0.1532
Hepatobiliary variables, n (%)
  Ascites in previous 30 d 0 (0.0%) 0 (0.0%) 0 (0.0%) >0.9999
  Esophageal varices in previous 6 mo 0 (0.0%) 0 (0.0%) 0 (0.0%) >0.9999
  Composite respiratory morbidity 0 (0.0%) 0 (0.0%) 0 (0.0%) >0.9999
Renal variables, n (%)
  Acute renal failure 2 (0.0%) 0 (0.0%) 2 (0.0%) >0.9999
  Presently on dialysis 5 (0.1%) 3 (0.2%) 8 (0.1%) 0.1362
  Composite renal morbidity 7 (0.1%) 3 (0.2%) 10 (0.1%) 0.2269
Neurological variables, n (%)
  Impaired sensorium in previous 48 h 0 (0.0%) 0 (0.0%) 0 (0.0%) >0.9999
  Hemiplegia 14 (0.2%) 4 (0.3%) 18 (0.2%) 0.5259
  Paraplegia 10 (0.1%) 1 (0.1%) 11 (0.1%) 0.7035
  Quadriplegia 0 (0.0%) 0 (0.0%) 0 (0.0%) >0.9999
  Coma lasting >24 h 0 (0.0%) 0 (0.0%) 0 (0.0%) >0.9999
  History of transient ischemic attacks 39 (0.5%) 13 (0.8%) 52 (0.6%) 0.1331
  History of CVA with neurological deficit 25 (0.3%) 3 (0.2%) 28 (0.3%) 0.6104
  History of CVA without neurological deficit 30 (0.4%) 8 (0.5%) 38 (0.4%) 0.4118
  Missing 2 (0.0%) 0 (0.0%) 2 (0.0%)
(Continued)
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Table 1. (Continued)
No Anemia Anemia Total
P
nno anemia = 7737 nanemia = 1556 nT = 9293
83.26% 16.74% 100%
  Tumor involving CNS 3 (0.0%) 1 (0.1%) 4 (0.0%) 0.5196
  Composite neurological morbidity 109 (1.4%) 26 (1.7%) 135 (1.5%) 0.417
Hemato-oncological variables, n (%)
  Bleeding disorder 49 (0.6%) 14 (0.9%) 63 (0.7%) 0.237
  Weight loss >10% in previous 6 mo 22 (0.3%) 16 (1.0%) 38 (0.4%) 0.0002
  Disseminated cancer 54 (0.7%) 28 (1.8%) 82 (0.9%) 0.0001
  Chemotherapy in previous 30 d 259 (15.55%) 155 (2.03%) 454 (4.14%) <0.0001
  Radiotherapy in previous 90 d 24 (0.3%) 13 (0.8%) 37 (0.4%) 0.0063
  Composite hemato-oncological variable 288 (3.7%) 294 (18.9%) 582 (6.3%) <0.0001
Other variables, n (%)
  Body mass index 0.8163
   Underweight 18.5 or less 300 (3.9%) 63 (4.0%) 363 (3.9%)
   Normal 18.5–24.9 2764 (35.7%) 541 (34.8%) 3305 (35.6%)
   Overweight 25–29.9 2167 (28.0%) 442 (28.4%) 2609 (28.1%)
   Obese 30 or more 2433 (31.4%) 506 (32.5%) 2939 (31.6%)
   Missing 73 (0.9%) 4 (0.3%) 77 (0.8%)
  Diabetic on oral drugs or insulin 254 (3.3%) 89 (5.7%) 343 (3.7%) <0.0001
  Alcohol intake in previous 2 wk§ 97 (1.3%) 9 (0.6%) 106 (1.1%) 0.0178
  Open wound (with or without infection) 26 (0.3%) 13 (0.8%) 39 (0.4%) 0.0094
  Steroid use for chronic condition 59 (0.8%) 19 (1.2%) 78 (0.8%) 0.0917
  Pregnancy 4 (0.1%) 2 (0.1%) 6 (0.1%) 0.2651
  Operation within previous 30 d 212 (2.7%) 47 (3.0%) 259 (2.8%) 0.5544
Preoperative laboratory studies, n (%)
  Serum sodium ≤135 mmol/L 102 (1.6%) 41 (3.0%) 143 (1.8%) 0.0007
  Missing 1201 (15.5%) 182 (11.7%) 1383 (14.9%)
  Serum sodium >145 mmol/L 56 (0.9%) 11 (0.8%) 67 (0.8%) >0.9999
  Missing 1201 (15.5%) 182 (11.7%) 1383 (14.9%)
  Blood urea nitrogen >14.3 mmol/L 2480 (32.1%) 456 (29.3%) 2936 (31.6%) 0.0006
  Missing 1368 (17.7%) 212 (13.6%) 1580 (17.0%)
  Serum creatinine >106.1 μmol/L 130 (1.7%) 47 (3.0%) 177 (1.9%) 0.0012
  Missing 997 (12.9%) 168 (10.8%) 1165 (12.5%)
  Mean serum albumin, g/L (SD) 4.2 (0.4) 4.1 (0.4) 4.2 (0.4) <0.0001
  Missing 3103 (40%) 555 (36%) 3658 (39%)
  Total bilirubin >1.9 mg/dL 162 (2.1%) 26 (1.7%) 188 (2.0%) 0.1854
  Aspartate aminotransferase >40 U/L 257 (5.2%) 72 (6.9%) 329 (5.5%) 0.0299
  Missing 2798 (36.2%) 517 (33.2%) 3315 (35.7%)
  Alkaline phosphatase >125 U/L 168 (2.2%) 58 (3.7%) 226 (2.4%) 0.0012
  Missing 2762 (35.7%) 511 (32.8%) 3273 (35.2%)
  White blood cell count >11,000 cells per μL 241 (3.1%) 75 (4.8%) 316 (3.4%) 0.0012
  Missing 241 (3.1%) 39 (2.5%) 280 (3.0%)
  Platelet count ≤150,000 cells per μL 133 (1.7%) 60 (3.9%) 193 (2.1%) <0.0001
  Missing 253 (3.3%) 44 (2.8%) 297 (3.2%)
  International normalized ratio >1.4 15 (0.2%) 6 (0.4%) 21 (0.2%) 0.2803
  Missing 5494 (71.0%) 1005 (64.6%) 6499 (69.9%)
Days from hematocrit measurement to  
 operation, n (%)
0.0078
  <14 5460 (70.6%) 1150 (73.9%) 6610 (71.1%)
  <28 2040 (26.4%) 352 (22.6%) 2392 (25.7%)
  <56 206 (2.7%) 46 (3.0%) 252 (2.7%)
  Missing 31 (0.4%) 8 (0.5%) 39 (0.4%)
*Work relative value unit is a scale (0–95) to quantify the amount of work involved in a specific surgery on the basis of preprocedural, intrap-
rocedural, and postprocedural time, technical skill, physical effort, mental effort and judgment, and stress due to potential risk; the scale is the 
work portion of the Resource-based Relative Value System adopted by US Medicare to quantify the amount of work involved in every medical 
procedure (score of 0 = least complex and 95 = most complex).
†ASA scores: I is a healthy patient; II is mild systemic disease but no functional limitations; III is severe systemic disease with definite functional 
limitations; IV is severe systemic disease that is a constant threat to life; and V is a moribund patient unlikely to survive 24 h with or without an 
operation.
‡Transfusion of more than 4 packed red blood cell units within 72 h preoperatively for the years 2008 and 2009, transfusion of at least 1 unit 
within 72 h preoperatively for 2010, any number of units transfused intraoperatively for all years, transfusion of more than 4 units within 72 h 
postoperatively for 2008 and 2009, or transfusion of at least 1 unit within 72 h postoperatively for 2010.
§More than 2 drinks per day.
ASA, American Society of Anesthesiologists; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular 
accident; HTN, hypertension requiring medications; WRVU, work relative value unit.
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Table 2. Logistic Models: Univariate and Multivariate Analyses
Postoperative 30-d Morbidity*
Odds Ratio P Confidence Interval
Logistic Model 1—Univariate Analysis: Unadjusted Estimates of Outcomes
  Anemia
   No Ref — —
   Yes 1.325 0.008 1.07–1.63
  BMI 1.012 0.022 1.00–1.02
  Age 1.013 0.001 1.00–1.02
  Smoking 1.255 0.040 1.01–1.56
  Race
   White Ref — —
   Black 1.345 0.037 1.02–1.77
   Hispanic 1.040 0.836 0.72–1.50
   Asian 0.742 0.252 0.45–1.23
   Others 1.017 0.903 0.77–1.34
  WRVU 1.022 0.099 0.99–1.04
  GA 0.981 0.974 0.30–3.16
  ASA
   I–II Ref — —
   III 1.77 <0.001 1.49–2.12
   IV 3.60 0.009 1.37–9.44
  Mean total operation time (min) 1.00 <0.001 1.00–1.00
  Inpatient 1.81 <0.001 1.42–2.29
  Days from admission to operation 1.33 0.139 0.91–1.96
  Functional status at the time of operation
   Independent Ref — —
   Dependent 1.27 0.658 0.44–3.66
  Diabetes 1.26 0.009 1.06–1.50
  Alcohol intake 0.88 0.762 0.41–1.91
  HTN 1.63 <0.001 1.38–1.93
  Steroid use 1.17 0.706 0.51–2.70
  Infected wound 3.06 0.007 1.36–6.90
  Previous operation within 30 d 1.94 <0.001 1.34–2.80
  Preoperative sodium
   ≤135 0.96 0.912 0.49–1.90
   >145 1.39 0.444 0.60–3.22
  Preoperative high BUN 0.92 0.393 0.76–1.11
  Preoperative high creatinine 1.17 0.588 0.66–2.07
  Preoperative high bilirubin 1.65 0.036 1.03–2.66
  Preoperative high SGOT 1.83 0.001 1.26–2.65
  Preoperative high alkaline phosphatase 1.32 0.270 0.81–2.16
  Days from hematocrit measurement to  
 operation
   <14 Ref — —
   <28 1.06 0.552 0.88–1.28
   <56 0.90 0.709 0.52–1.55
  Composite cardiovascular variables† 1.48 0.019 1.06–2.05
  Composite respiratory variables‡ 2.70 0.001 1.53–4.80
  Composite renal variables§ 8.97 <0.001 2.62–30.75
  Composite neurological variables¶ 2.51 <0.001 1.56–4.04
  Composite hemato-oncological variables║ 1.35 0.052 0.99–1.81
Logistic Model 2—Multivariate Regression: Extensive Adjustment
  Anemia
   No Ref — —
   Yes 1.38 0.037 1.02–1.85
  BMI 1.008 0.330 0.99–1.02
  Age 1.02 0.005 1.005–1.03
  Smoking 1.45 0.024 1.05–2.01
  Race
   White Ref — —
   Black 0.94 0.799 0.63–1.42
   Hispanic 0.83 0.483 0.50–1.38
   Asian 0.61 0.228 0.27–1.35
   Others 0.95 0.842 0.61–1.49
  WRVU 1.02 0.243 0.98–1.06
  GA 0.69 0.732 0.86–5.57
  ASA
(Continued)
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2010). These centers are located in the United States 
of America, Canada, Lebanon, the United Arab 
Emirates, and the United Kingdom.
We identified 2957 female patients who under-
went immediate breast reconstruction (our index 
surgery) in 2008, 3852 in 2009, and 4149 in 2010. 
These amounted to 10,958 patients. We excluded 
patients with missing preoperative hematocrit val-
ues (1665 patients) because this variable is used to 
define the exposure of interest. We performed the 
main analysis for 9293 patients.
We compared demographics, preoperative and 
intraoperative variables between patients without 
anemia and those with anemia (Table 1).
We used a modelwise approach and adjusted ex-
tensively for all parameters found to be statistically 
significant in our univariate analysis and for addi-
tional clinically relevant confounders (Table 2).
We then evaluated a potential dose-response re-
lationship between decreasing preoperative hemato-
crit and increasing 30-day morbidity. Point estimates 
reflecting the incidence of 30-day morbidity with 
decreasing hematocrit levels were calculated for all 
patients and plotted in Figure 1. We assessed further-
more the influence of baseline risk factors (comorbid 
conditions) on the association between preoperative 
anemia and morbidity. For this, we categorized pa-
tients into high- and low-risk groups based on rel-
evant risk factors and calculated point estimates of 
their 30-day morbidity incidence across different 
hematocrit levels (Fig. 1). Risk factors defining high-
risk group include age ≥65 years, smoking, infected/
Table 2. (Continued)
Postoperative 30-d Morbidity*
Odds Ratio P Confidence Interval
   I–II Ref — —
   III 1.24 0.12 0.94–1.62
   IV 0.34 0.33 0.04–3.04
  Mean total operation time (min) 1.003 0.00 1.003–1.004
  Inpatient 1.37 0.09 0.94–1.98
  Days from admission to operation 0.70 0.50 0.25–1.97
  Functional status at the time of operation
   Independent Ref — —
   Dependent 1.35 0.707 0.27–6.68
  Diabetes 0.99 0.984 0.76–1.30
  Alcohol intake 0.79 0.673 0.27–2.28
  HTN 1.07 0.627 0.80–1.43
  Steroid use 0.84 0.780 0.25–2.82
  Infected wound 3.64 0.040 1.06–12.47
  Previous operation within 30 d 2.02 0.011 1.17–3.49
  Preoperative sodium
   ≤135 0.96 0.942 0.40–2.30
   >145 1.19 0.748 0.40–3.50
  Preoperative high BUN 0.91 0.445 0.71–1.16
  Preoperative high creatinine 1.07 0.856 0.51–2.25
  Preoperative high bilirubin 1.84 0.027 1.07–3.16
  Preoperative high SGOT 1.54 0.045 1.01–2.36
  Preoperative high alkaline phosphatase 1.09 0.744 0.63–1.90
  Days from hematocrit measurement to operation
   <14 Ref — —
   <28 0.88 0.343 0.68–1.14
   <56 0.85 0.681 0.39–1.86
  Composite cardiovascular variables 1.25 0.354 0.78–1.99
  Composite respiratory variables 3.34 0.003 1.52–7.31
  Composite renal variables 5.01 0.083 0.80–31.07
  Composite neurological variables 2.03 0.029 1.07–3.86
  Composite hemato-oncological variables 1.10 0.655 0.71–1.69
*Wound events (superficial surgical site infections, deep surgical site infections, wound dehiscence) and cardiac, respiratory, urinary, flap/
prosthesis, and venous thromboembolism outcomes.
†Dyspnea at rest or with moderate exertion, congestive heart failure in previous 30 d, angina in previous 30 d, myocardial infarction in previous 
6 mo, previous percutaneous coronary intervention, previous cardiac surgery, history of peripheral vascular disease, rest pain, or gangrene.
‡Current pneumonia, history of severe COPD, ventilator dependent in previous 48 h.
§Acute renal failure, presently on dialysis.
¶Impaired sensorium in previous 48 h, hemiplegia, paraplegia, quadriplegia, coma lasting >24 h, history of transient ischemic attacks, history 
of CVA with neurological deficit, history of CVA without neurological deficit, tumor involving CNS.
║Bleeding disorder, weight loss >10% in previous 6 mo, disseminated cancer, chemotherapy in previous 30 d, radiotherapy in previous 90 d.
ASA, American Society of Anesthesiologists; BMI, body mass index; BUN, blood urea nitrogen; CNS, central nervous system; CVA, cerebrovas-
cular accident; GA, general anesthesia; HTN, hypertension requiring medications; SGOT, serum glutamic oxaloacetic transaminase; WRVU, 
work relative value unit (a measure of surgical complexity).
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dirty wound, perioperative transfusions, previous 
operation within 30 days, respiratory comorbidity 
(current pneumonia, history of severe chronic ob-
structive pulmonary disease, ventilator dependent in 
previous 48 h), renal comorbidity (acute renal failure, 
presently on dialysis), neurological comorbidity 
(impaired sensorium in previous 48 h, hemiplegia, 
quadriplegia, coma lasting >24 h, history of transient 
ischemic attack or cerebrovascular accident, central 
nervous system tumor), and some abnormal pre-
operative laboratory values (high serum glutamic 
oxaloacetic transaminase, high bilirubin). Pairwise 
Fisher’s exact tests with Bonferroni corrections were 
used to assess whether the difference in incidence 
per hematocrit group was statistically significant.
For the secondary outcome measure (increased 
LOS), we assessed the impact of postoperative ad-
verse events on LOS and the effect modification of 
preoperative anemia on this association (Fig. 2). We 
tested differences in measures of central tendency 
(mean and median) and measures of variability (in-
terquartile range and variance) between increasing 
levels of anemia after stratifying for the presence or 
absence of an adverse event. Kruskal-Wallis rank sum 
test with Bonferroni corrections was used to assess 
significance (Table 4).
Procedures
All female patients who underwent immediate 
breast reconstruction from 2008 to 2010 were identi-
fied using the following Current Procedural Termi-
nology (CPT) codes: 19160, 19301, 19162, 19302, 
19180, 19303, 19182, 19304, 19200, 19305, 19220, 
19306, 19307, 19240 for mastectomy and 19340, 
19342, 19357, 19361, 19364, 19366, 19367, 19368, 
19369 for breast reconstruction. Patients coded si-
multaneously 2 CPTs (one from the mastectomy list 
and another from the breast reconstruction list) de-
fine the immediate breast reconstruction population.
We defined preoperative hematocrit concentra-
tion as the last hematocrit measurement before the 
index surgery and preoperative anemia as a hema-
tocrit concentration <36% (World Health Organi-
zation criteria).12 Hematocrit concentration >29% 
Fig. 1. Dose-response curve of incidence of 30-d morbidity events for high- and low-risk 
groups vs preoperative hematocrit level. the incidence of 30-d morbidity with 95% ci is cal-
culated for patients in 5 different categories of preoperative hematocrit level: <30.0, 30.0–
32.9, 33–35.9, 36–38.9, and ≥39.
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to <36% was defined as mild anemia and ≤29% as 
moderate-to-severe anemia.
Postoperative outcomes were morbidity within 
30 days and increased LOS. Morbidity variables in-
cluded events affecting the graft (prosthesis or flap 
failure), heart (acute myocardial infarction), respi-
ratory tract (pneumonia), central nervous system 
(cerebrovascular accident), urinary tract (infection), 
wound (superficial and deep incisional surgical 
site infection and wound dehiscence), and venous 
thromboembolism events (deep venous thrombosis 
requiring therapy and pulmonary embolism). LOS 
was defined as the date of discharge minus the date 
of surgery.
Statistical Analysis
Continuous variables, such as age, are presented 
with their mean and standard deviation as “mean 
(SD),” whereas categorical variables, such as gender, 
are presented as the number of patients and its cor-
responding proportion with respect to the exposure 
group, “n (%).” P-values for continuous variables 
correspond to a Kruskal-Wallis rank sum test of the 
null assuming the location parameters of the distri-
bution of the variable are the same in each exposure 
group. P-values for categorical variables correspond 
to a Fisher’s exact test for testing the null of indepen-
dence of rows and columns in a contingency table 
with fixed marginal (Table 1).
For the primary study outcome (occurrence of 
morbidity within 30 d of surgery), adjusted odds ra-
tio reflecting 30-day morbidity was estimated using 
a multivariable logistic regression model comparing 
patients in the preoperative anemia group to those 
with no anemia.
Data management and analyses were done with 
STATA/SE 11, and graphs were plotted using R 
2.15.1. All tests excluded missing values; their fre-
quencies are reported in the Appendix (Supplemen-
tal Digital Content 1, http://links.lww.com/PRSGO/
A3). Authors had full access to and take full respon-
sibility for the integrity of the data.
Ethical Approval
De-identified patient information is freely avail-
able to all institutional members who comply with 
the ACS-NSQIP Data Use Agreement. The Data Use 
Agreement implements the protections afforded by 
the Health Insurance Portability and Accountability 
Act of 1996 and the ACS-NSQIP Hospital Participa-
tion Agreement. This study conforms to the Helsinki 
Declaration.
Fig. 2. effect modification of preoperative anemia levels on the association between post-
operative adverse events and lOS. anemia significantly amplified lOS in patients with low 
preoperative hematocrit experiencing an adverse event as compared to patients with low 
preoperative hematocrit not experiencing an adverse event.




We included data for 9293 patients. We obtained 
hematocrit concentrations for 9042 (97.3%) pa-
tients within approximately 2 months of surgery 
[6644 (71.5%) were obtained within 14 d]. Preop-
erative anemia was present in 16.7% of our cohort. 
Data were almost complete, apart from some missing 
laboratory variables, such as serum sodium (17.9%), 
blood urea nitrogen (17.0%), serum creatinine 
(12.5%), serum albumin (39%), aspartate amino-
transferase (35.7%), alkaline phosphatase (35.2%), 
and international normalized ratio (69.9%).
Demographics and medical history are summa-
rized in Table 1. Patients had a mean age of 51.5 
years (SD, 10.5; range, 18–95). Compared with pa-
tients without anemia, patients with anemia were 
more likely to have a higher body mass index and 
a race other than white. Patients with anemia also 
had a higher prevalence of diabetes and cardiovas-
cular disorders; they were more likely to be at a high 
American Society of Anesthesiologists class and non-
independent in functional status. Furthermore, they 
were more likely to have disseminated cancer, have 
received chemo or radiotherapy, present with abnor-
mal preoperative laboratory studies, and undergo 
perioperative transfusions. However, they had lower 
age and prevalence of smoking.
Univariate analysis revealed that several preopera-
tive factors (Table 2) were associated with significant-
ly higher odds of 30-day morbidity. The cumulative 
incidence of 30-day morbidity was 5.9% for patients 
without anemia compared with 7.6% for patients 
with anemia, with an unadjusted odds ratio of 1.33 
and 95% confidence interval (CI) of 1.07–1.63.
After adjustment for statistically significant and 
clinically relevant confounders (Table 3), preop-
erative anemia remained independently and signifi-
cantly associated with increased 30-day morbidity 
(adjusted odds ratio, 1.38; 95% CI, 1.02–1.85).
Furthermore, univariate analysis established a 
primary association between decreased preoperative 
hematocrit and increased postoperative morbidity. 
Figure 1 illustrates the dose-dependent nature of 
this effect. We also observed a dose-response effect 
when patients were categorized into high/low risk, 
with a significantly higher incidence of 30-day mor-
bidity in high-risk patients for hematocrit groups of 
30% or higher.
We further analyzed the implication of postopera-
tive morbidity on LOS and examined whether the 
occurrence of morbidity reached synergy with differ-
ent severities of preoperative anemia. As expected, 
LOS was increased in the presence of postoperative 
adverse events (mean, 3.23; SD, 2.62) compared to 
patients who experienced no complications (mean, 
2.06; SD, 1.61). However, for the subpopulation of 
patients having preoperative low hematocrit and 
developing a postoperative adverse event, anemia 
significantly amplified LOS as compared to the sub-
population with low preoperative hematocrit and 
not experiencing an adverse event (Fig. 2). Figure 2 
illustrates the effect modification of anemia on the 
association between LOS and adverse events.
Table 3 complements Figure 2 and provides all 3 
pairwise comparisons.
Finally, anemia may have served as an indica-
tion to receive a transfusion in this cohort. In fact, 
because anemia can potentially lead to both the 
occurrence of transfusions and adverse events, we 
expected an association between anemia and trans-
fusions. Indeed, while 1.7% of patients without 
anemia required transfusions, 2.9% of those with 
anemia underwent transfusions (Pearson’s chi-
square(1), 11.9; P < 0.001). In our analysis, transfu-
sions predicted the occurrence of 30-day morbidity 
(unadjusted odds ratio, 38.48; 95% CI, 26.68–55.51). 
In other words, transfusions seem to represent a sur-
rogate outcome of morbidity (or an alternative way 
of measuring it).
DISCUSSION
This large epidemiological study is the first to 
investigate the nature and extent of preoperative 
Table 3. Pairwise Comparisons of Length of Hospital Stay Within the Different Hematocrit Levels Between 
Patients Who Experienced an Adverse Event and Those Who Did Not
Hematocrit Level Adverse Event Mean Median Range (d) SD n P *
No anemia (≥36%) No† 2.01 2.0 0–13 1.31 7282 <0.001Yes 3.14 2.0 0–16 2.36 455
Mild anemia (>29% to <36%) No† 2.18 2.0 0–9 1.38 1365 <0.005Yes 3.21 3.0 0–12 2.40 109
Moderate-to-severe anemia (≤29%)
No† 2.26 2.0 1–12 1.83 72
<0.05Yes 4.50 4.5 3–6 1.49 10
*P-values correspond to Kruskal-Wallis rank sum tests comparing location parameters (central tendency) with Bonferroni correction to account 
for multiple comparisons.
†The reference group for all 3 pairwise comparisons is patients experiencing no postoperative adverse events.
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anemia on postoperative outcomes in patients un-
dergoing immediate breast reconstruction. Using a 
comprehensive worldwide multicenter prospective 
database, we showed that preoperative anemia is in-
dependently associated with an increased risk of 30-
day morbidity. In addition, when anemia was present 
concomitantly with a known preoperative risk factor, 
it led to a significant increase in the effect of this 
risk factor on 30-day morbidity. Furthermore, ane-
mia amplified the LOS for patients who experienced 
postoperative adverse events. This suggests that pa-
tients having baseline risk factors predisposing them 
to a postoperative adverse event (Table 3) may have 
significantly higher LOSs if preoperative anemia is 
present. This risk may be further increased when 
anemia is moderate to severe.
The observed effects of anemia on 30-day mor-
bidity and LOS were evident across all types of imme-
diate reconstruction and aspects of medical history 
(age, race, body mass index, smoking, diabetes, hy-
pertension requiring medications, previous chemo 
or radiotherapy, etc.). They were also observed irre-
spective of the duration from hematocrit measure-
ment to operation.
This association between low hematocrit and in-
creased adverse outcomes has been described for a 
variety of surgical patient populations: vascular, or-
thopedic, cardiac, and major noncardiac surgery 
patients.13–16 Few studies have attempted examining 
the role of preoperative anemia in patients undergo-
ing breast reconstruction. Vega et al5 suggested that 
a relative preoperative anemia state caused by autol-
ogous blood donation leads to a greater frequency 
of surgical morbidity in free transverse rectus abdo-
minus myocutaneous flap breast reconstruction. Fur-
thermore, Hill et al6 demonstrated that preoperative 
anemia is a significant predictor of free flap failure 
and vascular thrombosis in general microvascular re-
construction. They added that flap failure had a sta-
tistically significant exposure-response relationship 
to anemia, with the probability of failure increasing 
incrementally with decreases in preoperative hema-
tocrit. Moreover, Ting et al7 pointed out that preop-
erative anemia might negatively impact deep inferior 
epigastric perforators flap survival and patient mor-
bidity in breast reconstruction because transfusion 
requirements are increased. Our study reinforces 
these findings and suggests that the detrimental ef-
fects of preoperative anemia occur across all types of 
immediate reconstruction. In addition, they are asso-
ciated with a higher risk of major morbidity, includ-
ing graft, wound, cardiac, respiratory, neurological, 
urinary, and thromboembolic complications.
It also demonstrated a dose-dependent sig-
nificant increase in morbidity with decreasing he-
matocrit levels. This suggests that the effect of an 
underlying disease or risk factor on postoperative 
adverse events is amplified by the presence of ane-
mia. Similarly, anemia seems to amplify LOS in pa-
tients having risk factors predicting the occurrence 
of adverse events (Table 2).
The key strengths of our study are the large num-
ber of patients and the reliable and comprehensive 
data collection of the ACS-NSQIP. This database pro-
vides more than 60 demographic, preoperative, and 
perioperative variables for adjustment. Our study 
adjusted for extensive confounding. This complete-
ness, together with the good discrimination in our 
model, suggests that the effect of anemia is inde-
pendent and cannot be straightforwardly explained 
through an association with other known risk factors.
Our findings should lead to a careful consider-
ation of appropriate interventions to correct preop-
erative anemia in patients undergoing immediate 
breast reconstruction. Preoperative diagnosis and 
treatment of anemia (apart from transfusions of 
red blood cells) have almost never been undertaken 
routinely before surgery.17 Our study supports the 
present guidelines recommending measuring hema-
tocrit concentration 28 days before surgery and sub-
sequent investigations in anemic patients. At least 
in elective surgical cases (such as immediate breast 
reconstruction), it is strongly recommended to treat 
preoperative anemia; it is easy to detect and, in many 
situations, inexpensive to treat.1 Proactive treatment 
is likely less costly than postoperative transfusions 
and may improve patient outcomes and decrease 
LOS, which often translate into reduced health care 
costs, a growing national health care concern.
Our study had limitations. Approximately 3% of 
the preoperative hematocrit concentrations were ob-
tained >7 weeks before surgery and might not accu-
rately predict hematocrit concentrations at the time 
of surgery. Still, variations in hematocrit are usually 
low in the absence of an emergency operation or 
major bleeding, which in our database would have 
been identified by preoperative packed red blood 
cell transfusions; these occurred in 0.03% of the pa-
tients only. However, it is worth noting that NSQIP 
does not indicate the use of 4 or fewer transfusions 
in the preoperative period for the years 2008 and 
2009, which means that some patients viewed in the 
analysis as not having received preoperative transfu-
sions might have received 4 or fewer transfusions. 
Nevertheless, about 99.4% of patients without doc-
umented preoperative transfusions in these 2 years 
underwent same-day surgery, suggesting that preop-
erative transfusion was unlikely and they indeed had 
a significant association between anemia and postop-
erative adverse outcomes.
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Additionally, the long-term effects of the multiple 
transfusions cancer patients often receive could not 
be accounted for in the analysis. This is due to the 
nature of the NSQIP database which does not pro-
vide the number of all previous transfusions.
Finally, given the retrospective nature of our 
study, we cannot determine the causal relationship 
between low hematocrit and risk of postoperative ad-
verse events. Neither can we relate the etiology nor 
chronicity of abnormal hematocrit with outcomes.
Nevertheless, our study strongly suggests that 
implementation of anemia screening and treatment 
should be considered in patients undergoing im-
mediate breast reconstruction. A future interesting 
study entails subdividing immediate breast recon-
struction into autologous and implant based and 
comparing in these 2 cohorts the incidence of 30-day 
morbidity associated with preoperative anemia. This 
analysis is not possible in NSQIP; this database uses 
CPT codes to identify types of reconstruction, and 
some CPTs do not differentiate between autologous 
and implant-based reconstruction (eg, CPT 19361 
refers to breast reconstruction with latissimus dorsi 
with or without implant, although that code is now 
modified so it should be possible in the future).
Additional prospective studies are needed to de-
termine whether our findings are also reproducible 
in other breast surgery populations (namely, delayed 
breast reconstruction, mastectomy alone) and to as-
sess the efficacy, safety, and cost-effectiveness of pre-
operative anemia management in immediate breast 
reconstruction. 
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